Bictegravir (INN; BIC) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. In vitro and clinical results were presented by Gilead in the summer of 2016.
Bictegravir (INN; BIC) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. In vitro and clinical results were presented by Gilead in the summer of 2016.
Source: Wikipedia "Bictegravir" · CC BY-SA 4.0
Share this article: X · Bluesky